​Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 21, Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock with a $31 price target. Earlier, on January 14, BTIG reiterated a Buy rating on the stock with a $30 price target. Analysts at BTIG noted that the bullish sentiment follows the company’s recently highlighted key 2026 objectives. Management highlighted that their bexdeg, which is a BTK degrader for relapsed chronic lymp ...

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $0.75 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.88%. A quarter ago, it was expected that this company would post a loss of $0.84 per share when it actually produced a loss of $1.03, delivering a surprise of -22.62%.Over the last four quarters, the company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________ __________________FORM _____________________________10-K ____________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD ...

[Nurix logo] Exhibit 99.1 Recent Business Highlights Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile in relapsed/refractory CLL 83% objective overall response rate and progression free survival of 22.1 months demonstrate durable therapeutic ef ects ...

First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg’s potential best-in-class profile in relapsed/refractory CLL 83% objective overall response rate and progression free survival of 22.1 months demonstrate durable therapeutic effects in a large portion of patients Presented differentiated preclinical data for IRAK4 degrader GS-6791 in collaboration with Gilead Well capitalized with cash and marke ...

Core Insights - Nurix Therapeutics (NRIX) is positioned to make significant advancements in the treatment of Chronic Lymphocytic Leukemia (CLL) and immune diseases, indicating a potential shift in therapeutic approaches within this market [1] Industry Overview - The CLL treatment market has been predominantly controlled by BTK inhibitors, specifically Ibrutinib and Pirtobrutinib, highlighting the competitive landscape and the challenges faced by new entrants [1]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Viewpoint - Nurix Therapeutics is focused on establishing degrader-based mechanisms as a significant new class of therapeutics in patient care [3]. Company Overview - Nurix Therapeutics is dedicated to advancing targeted protein degraders, which represent an emerging category of small molecule drugs [3][4]. - The company positions these targeted protein degraders as potentially as impactful as antibodies and shares similarities with nucleic acid-based therapies [5]. Industry Context - The evolution of therapeutics has seen limited innovation in small molecule inhibitors until the introduction of targeted protein degraders, which are now viewed as a major advancement in the field [4].

Nurix Therapeutics FY Conference Summary Company Overview - **Company**: Nurix Therapeutics (NasdaqGM:NRIX) - **Event**: 44th Annual JPMorgan Healthcare Conference - **Date**: January 12, 2026 Key Industry Insights - **Emerging Class of Drugs**: Nurix is focused on establishing degrader-based mechanisms as a new class of therapeutics, which are expected to be as significant as antibodies and nucleic acid-based therapies [2][3] - **Targeted Protein Degraders**: These small molecule drugs can knock down protein levels effectively and are orally deliverable, offering a broader market opportunity compared to traditional therapies [3][4] Core Company Highlights - **2025 Achievements**: - Entered pivotal trials with Daybreak 201 study for CLL (Chronic Lymphocytic Leukemia) [4] - Reported an 83% objective overall response rate in heavily pre-treated patients [4][5] - Calculated a progression-free survival (PFS) of 22.1 months across all doses tested [5][16] - Secured a strong financial position with $250 million from a follow-on offering and approximately $650 million in cash and investments [6] Pipeline Developments - **Bexabrutadeg**: Lead BTK (Bruton’s Tyrosine Kinase) degrader, currently in pivotal studies with promising results [5][6] - **Partnerships**: Collaborations with Gilead for IRAK4 degrader and Sanofi for STAT6 degrader, both in various stages of clinical trials [6][29] - **Upcoming Trials**: - Phase 3 confirmatory study against Pirtobrutinib, a non-covalent inhibitor, to demonstrate the superiority of degraders [24][25] - Combination studies with Bexabrutadeg and other agents like Venetoclax and rituximab [26] Competitive Positioning - **Best-in-Class Potential**: Bexabrutadeg is positioned as a potential best-in-class agent due to its unique degradation mechanism, which is expected to outperform traditional inhibitors [35][42] - **Comparative Efficacy**: Bexabrutadeg shows a higher overall response rate (83%) compared to Pirtobrutinib (65%) and a longer median duration of response [20][21] Market Opportunities - **Large Patient Population**: Approximately 60,000 patients initiate treatment annually in the second and third lines, with current BTK inhibitor sales at $12.5 billion per year [27] - **Expansion into Autoimmune Diseases**: Plans to explore Bexabrutadeg in autoimmune indications, leveraging its safety profile and efficacy [28][45] Financial and Strategic Outlook - **Financial Health**: Strong balance sheet with significant cash reserves to support ongoing and future trials [6] - **Strategic Focus**: Aiming to establish a substantial IND portfolio covering multiple indications, with a focus on de-risking oncology products [32][33] Additional Insights - **Resistance to Current Therapies**: Bexabrutadeg is effective against all known resistance mutations associated with BTK inhibitors, providing a significant advantage in treatment [12][21] - **CNS Activity**: Notable efficacy in treating CNS involvement in CLL, opening avenues for non-malignant CNS diseases like multiple sclerosis [44] Conclusion Nurix Therapeutics is positioned at the forefront of a transformative approach in oncology and autoimmune disease treatment through its innovative degrader technology, with a robust pipeline and strategic partnerships that enhance its competitive edge in the market.

Bexobrutideg Clinical Trial and Data - Bexobrutideg achieved an 83% objective response rate (ORR) in relapsed/refractory CLL patients in Phase 1a trials[8, 26, 32, 40] - The median progression-free survival (PFS) for Bexobrutideg was 22.1 months across all doses tested in the Phase 1a study[8, 26, 32, 40] - In a Phase 1b randomized cohort, the 600 mg dose of Bexobrutideg showed an 83.3% objective response rate[37, 38] - Nurix initiated the pivotal DAYBreak-201 Phase 2 study to support accelerated approval of bexobrutideg in relapsed/refractory CLL[8, 43] - A confirmatory Phase 3 trial is planned to start in 2026 to position Bexobrutideg for full approval[58] Pipeline and Partnerships - Nurix has a strengthened financial position with $663.8 million in pro forma cash/investments[8] - Nurix earned $47 million in non-dilutive capital through discovery partnerships[8] - The IRAK4 degrader is in an ongoing Phase 1 SAD/MAD study with partner Gilead[8, 9] - The STAT6 degrader advanced to IND-enabling studies with partner Sanofi[8, 9] Bexobrutideg Mechanism and Advantages - Bexobrutideg is a BTK degrader that removes both BTK enzymatic activity and scaffolding functions, unlike BTK inhibitors[10, 12] - Bexobrutideg demonstrates superior mutational coverage compared to BTK inhibitors[19, 20] - Bexobrutideg is the only BTK degrader to demonstrate clinical activity in patients with CNS disease, including complete responses[22] Market and Strategy - The current BTK inhibitor market is annualizing at $12.5 billion, with approximately $9.5 billion in CLL[55] - Nurix has a clinical development plan addressing large segments of the CLL market as both a mono- and combo- therapy[54]